Medicare Part D Premiums Are Rising in 2027: Your Subsidy Is Ending
Millions of seniors face higher drug costs as a key federal subsidy sunsets, a change largely overshadowed by discussion of out-of-pocket caps.
The direct answer
The conventional wisdom surrounding Medicare Part D in 2027 focuses on the new $2,400 out-of-pocket spending cap, a seemingly positive development. However, this narrative conveniently omits a critical underlying change: the expiration of a federal subsidy that has been artificially lowering Part D premiums for years
Today, CMS released the Calendar Year 2027 Medicare Advantage (MA) and Part D Rate Announcement to improve payment accuracy and competition across both programs. The finalized policies also advance CMS’ vision of a sustainable and stable MA program that offers high-quality…
— CMSGov link
. Starting in 2027, this subsidy will end, leading to a significant increase in monthly premiums for millions of beneficiaries. The Centers for Medicare & Medicaid Services (CMS) announced finalized policies for the 2027 contract year, which include this subsidy phase-out, aiming for "long-term sustainability" of the program
Centers for Medicare & Medicaid Services (CMS) Reports Finalizing 2027 Medicare Advantage and Part D Payment Policies Saying it Strengthens Accountability and Long-Term Sustainability https://t.co/3nqV9lpVUS
— SIERRA SUN TIMES link
. While the exact premium hikes will vary by plan and region, the removal of this support means seniors will likely see a noticeable jump in their regular drug plan costs, independent of the new out-of-pocket maximum. This shift is designed to align payments more closely with actual costs, a move that benefits insurers like UnitedHealth and Humana, whose stocks saw positive reactions to the finalized payment rates
$UNH , $HUM , and $OSCR shares are trading higher after CMS finalized a 2.48% average increase in 2027 Medicare Advantage payments, above expectation. https://t.co/0Z0Mf28Abh
— Wall St Engine link
. The focus on the out-of-pocket cap, while important, distracts from the immediate, ongoing cost increase that will impact nearly every Part D enrollee.
The Hidden Premium Hike
While the $2,400 out-of-pocket cap for prescription drugs under Medicare Part D for 2027 is a significant change, it’s been presented in a vacuum. What’s largely being overlooked is the simultaneous expiration of a federal subsidy that has been propping up monthly Part D premiums
Today, CMS released the Calendar Year 2027 Medicare Advantage (MA) and Part D Rate Announcement to improve payment accuracy and competition across both programs. The finalized policies also advance CMS’ vision of a sustainable and stable MA program that offers high-quality…
— CMSGov link
. This subsidy, a form of government support, has helped keep premium costs lower than they would otherwise be. Its removal means that beneficiaries will see their regular monthly payments for Part D plans increase, a cost that will be felt consistently, month after month, regardless of their drug utilization. The CMS finalized these payment policies for the 2027 contract year, signaling a move towards a more market-driven, less subsidized model
Centers for Medicare & Medicaid Services (CMS) Reports Finalizing 2027 Medicare Advantage and Part D Payment Policies Saying it Strengthens Accountability and Long-Term Sustainability https://t.co/3nqV9lpVUS
— SIERRA SUN TIMES link
. This isn't a hypothetical future; it's a concrete policy change impacting nearly every senior enrolled in a Part D plan.
Why Now? The 'Sustainability' Gambit
The official reasoning behind ending the federal subsidy for Part D premiums in 2027 is couched in terms of 'improving payment accuracy and competition' and ensuring 'long-term sustainability' [c1, c3]. In plain English, this means the government is stepping back from subsidizing the program to a degree that makes it more profitable for the private insurance companies administering Part D plans. Companies like UnitedHealth, Humana, and Oscar Health have seen their stock prices react positively to these finalized policies, indicating that the changes are favorable to their bottom lines
$UNH , $HUM , and $OSCR shares are trading higher after CMS finalized a 2.48% average increase in 2027 Medicare Advantage payments, above expectation. https://t.co/0Z0Mf28Abh
— Wall St Engine link
. Dr. Albert Alan notes that these finalized rules have 'meaningful takeaways' for these major players
$UNH $CLOV $HUM $ALHC Today CMS dropped its final rule for how Medicare Advantage and Part D drug plans will work starting in contract year 2027, and there are some meaningful takeaways for anyone holding shares in companies like UnitedHealth, Humana, or Clover Health. The…
— Albert Alan, MD link
. Essentially, the industry is being given a boost through higher premium revenue, while the burden shifts to the beneficiaries. It's a classic case of the government facilitating industry profits under the guise of fiscal responsibility.
Beyond the Cap: What Your Monthly Bill Will Look Like
The $2,400 out-of-pocket cap is a ceiling, meaning you won't pay more than that for covered drugs in a given year. However, the expiring subsidy directly impacts the floor – your monthly premium. While specific premium increases for 2027 are not yet finalized and will vary by plan, the removal of the subsidy is expected to cause a noticeable rise. For instance, if a plan's unsubsidized premium was projected to be $50 per month, but a subsidy kept it at $30, seniors could see that premium jump back up to $50 in 2027. This means an additional $240 or more per year in drug costs, purely from the premium increase, before even considering the cost of medications. This ongoing expense is separate from and in addition to any changes in drug costs or the new out-of-pocket maximum.
Common mistakes
- Focusing solely on the out-of-pocket cap.
This overlooks the concurrent expiration of a federal subsidy that directly increases monthly premiums, a cost that affects all beneficiaries, not just those with high drug expenses. - Presenting the premium increase as an abstract possibility rather than a concrete policy change.
The CMS has finalized policies for 2027 [c1, c3], meaning this subsidy phase-out and subsequent premium rise are definite, not speculative, and will impact millions. - Ignoring the financial beneficiaries of the policy change.
The positive stock market reactions from major insurance companies like UnitedHealth and Humana [c2, c4] highlight that this 'sustainability' measure primarily benefits the industry, not necessarily the seniors paying the bills.
Today, CMS released the Calendar Year 2027 Medicare Advantage (MA) and Part D Rate Announcement to improve payment accuracy and competition across both programs. The finalized policies also advance CMS’ vision of a sustainable and stable MA program that offers high-quality…
— CMSGov link
. This isn't just a minor adjustment; it's a fundamental shift that will increase the ongoing monthly costs for millions of seniors. The CMS is framing this as necessary for 'long-term sustainability' and 'payment accuracy'
Centers for Medicare & Medicaid Services (CMS) Reports Finalizing 2027 Medicare Advantage and Part D Payment Policies Saying it Strengthens Accountability and Long-Term Sustainability https://t.co/3nqV9lpVUS
— SIERRA SUN TIMES link
, which is industry speak for ensuring insurance companies like UnitedHealth and Humana remain profitable [c2, c4]. This policy change prioritizes the financial health of the insurance industry over the immediate affordability of prescription drugs for beneficiaries. Seniors need to understand that their monthly bills are going up, not just their potential maximum spend.
Frequently asked
When will the Medicare Part D subsidy end?
The federal subsidy that has helped keep Medicare Part D premiums lower is set to expire as part of the finalized policies for the 2027 contract year, announced by the CMS [c1, c3]. This means beneficiaries should anticipate higher monthly premiums starting in January 2027.
How much will my Part D premium increase?
The exact increase will vary by individual Part D plan and location, as premiums are determined by various factors. However, the removal of the federal subsidy is expected to cause a noticeable rise for most beneficiaries, potentially adding hundreds of dollars annually to drug plan costs.
Is the $2,400 out-of-pocket cap still a good thing?
Yes, the $2,400 out-of-pocket cap for prescription drugs in 2027 is a significant protection for those with very high medication costs. However, it does not offset the ongoing increase in monthly premiums due to the expiring subsidy, which will affect nearly everyone enrolled in Part D.
